KV Pharmaceutical Company

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

160 documents for KV Pharmaceutical Company

- 11 Allen LeFaivre v. KV Pharmaceutical Company, (8th Cir. 2011)
United States Court of Appeals FOR THE EIGHTH CIRCUIT ...
- Federal Circuits
- U.S. Court of Appeals, 8th Circuit Case Summaries: March 11, 2011
LeFaivre v. KV Pharmaceutical Company, et al. (MLW No. 61906/ Case No. 10-1326 - 14 pages) (U.S. Court of Appeals, 8th Circuit, Smith, J.) Civil Practice
- Missouri Lawyers Media
- March 18, 2011
- 11 KV Pharmaceutical Company v. J. Uriach & CIA, (8th Cir. 2011)
United States Court of Appeals FOR THE EIGHTH CIRCUIT ...
- Federal Circuits

- 11 Allen LeFaivre v. KV Pharmaceutical Company, (8th Cir. 2011)
United States Court of Appeals FOR THE EIGHTH CIRCUIT ...
- Federal Circuits
- Kv Pharmaceutical Voluntarily Suspends All Shipments of Its Approved Tablet-Form Drugs
To: HEALTH EDITORS Contact: Catherine Biffignani of KV Pharmaceutical Company, +1- 314-645-6600, cbiffignani@kvpharmaceutical.com
- U.S. Newswire
- December 23, 2008
- In re Metoprolol Succinate Patent Litigation, Astrzeneca AB, et al. v. KV Pharmaceutical Company, et al., (Fed. Cir. 2007)
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT 20 IN RE METOPROLOL SUCCINATE PATENT LITIGATION ASTRAZENECA AB, AKTIEBOLAGET HASSLE, and AS...
- Federal Circuits
- In re Metoprolol Succinate Patent Litigation, Astrzeneca AB, et al. v. KV Pharmaceutical Company, et al., (2007)
United States Court of Appeals for the Federal Circuit IN RE METOPROLOL SUCCINATE PATENT LITIGATION ------------------------------------------------...
- United States Court of Appeals for the Federal Circuit
- Cohen Milstein Announces That It Has Filed A Securities Class Action Lawsuit Against KV Pharmaceutical Company.
WASHINGTON -- The law firm of Cohen Milstein Sellers & Toll PLLC has filed a lawsuit on behalf of its client and a proposed class of persons who purch...
- Business Wire
- January 10, 2009
- Robbins Umeda LLP Announces Investigation of KV Pharmaceutical Company.
SAN DIEGO -- Robbins Umeda LLP has commenced an investigation into possible mismanagement of KV Pharmaceutical Company ("KV" or the "Company") (NYSE: ...
- Business Wire
- January 28, 2010
- Drug to Stop Preemie Births Gets Price Cut
ATLANTA - The maker of an expensive drug to prevent premature births slashed the price by more than half on Friday, following an outcry over the high cost and moves by federal regulators to keep a cheap version available. The drug is still pricey at $690 per weekly injection, but it is a drastic reduction from the $1,500 charged by KV Pharmaceutical Co. when it went on the market last month. The company also announced rebates and other steps to give the drug to needy pregnant women at little or no cost.
- The Commercial Appeal (2007-Current)
- April 04, 2011